Abstract-Nitric oxide (NO) is an important modulator of cardiac performance and left ventricular (LV) remodeling after myocardial infarction (MI). We tested the effect of cardiomyocyte-restricted overexpression of one NO synthase isoform, NOS3, on LV remodeling after MI in mice. LV structure and function before and after permanent LAD coronary artery ligation were compared in transgenic mice with cardiomyocyte-restricted NOS3 overexpression (NOS3-TG) and their wild-type littermates (WT). Before MI, systemic hemodynamic measurements, echocardiographic assessment of LV fractional shortening (FS), heart weight, and myocyte width (as assessed histologically) did not differ in NOS3-TG and WT mice. The inotropic response to graded doses of isoproterenol was significantly reduced in NOS3-TG mice. One week after LAD ligation, the infarcted fraction of the LV did not differ in WT and NOS3-TG mice (34Ϯ4% versus 36Ϯ12%, respectively). Four weeks after MI, however, end-systolic LVID was greater, and fractional shortening and maximum and minimum rates of LV pressure development were less in WT than in NOS3-TG mice. LV weight/body weight ratio was greater in WT than in NOS3-TG mice ( remodeling occurs as an adaptive process by which the myocardium changes shape, size, and function in response to increased mechanical and neurohumoral stress. These adaptations include scar maturation and both eccentric and concentric hypertrophy of remote myocardium to compensate for myocardial loss and increase in wall stress. 1 In case of insufficient compensation, LV remodeling becomes maladaptive leading to ventricular dilatation, overt heart failure, and compromised survival. 2 Nitric oxide (NO) modulates many processes contributing to LV performance including ventricular compliance, myocardial preload and afterload, reperfusion injury, 3-5 and angiogenesis. 6 NO may stimulate new vessel recruitment in ischemic myocardium, 7 reduce excessive myocyte hypertrophy, and limit extracellular matrix deposition and myocardial fibrosis. 8, 9 NO is generated by three NO synthase isoforms, neuronal NOS1, inducible NOS2, and endothelial NOS3. In cardiac myocytes, NOS3 is targeted to caveolae 10,11 where compartmentalization with ␤-adrenergic receptors and L-type Ca 2ϩ channels allows NO to inhibit ␤-adrenergic-induced inotropy. 12 Neuronal NO synthase (NOS1) is localized to cardiac sarcoplasmic reticulum and modulates myocardial contractility via intracellular calcium cycling. 13, 14 Increased cardiac NOS1-derived NO production has been suggested to play an important autocrine regulatory role to maintain myocardial contractility after MI in aging rats. 15 We tested the effect of increased myocardial NOS3 expression on LV remodeling after MI. We compared hemodynamic and echocardiographic parameters of LV performance after MI in transgenic mice with cardiomyocyte-restricted overexpression of human NOS3 (NOS3-TG) and in wild-type (WT)
A fter myocardial infarction (MI), left ventricular (LV) remodeling occurs as an adaptive process by which the myocardium changes shape, size, and function in response to increased mechanical and neurohumoral stress. These adaptations include scar maturation and both eccentric and concentric hypertrophy of remote myocardium to compensate for myocardial loss and increase in wall stress. 1 In case of insufficient compensation, LV remodeling becomes maladaptive leading to ventricular dilatation, overt heart failure, and compromised survival. 2 Nitric oxide (NO) modulates many processes contributing to LV performance including ventricular compliance, myocardial preload and afterload, reperfusion injury, [3] [4] [5] and angiogenesis. 6 NO may stimulate new vessel recruitment in ischemic myocardium, 7 reduce excessive myocyte hypertrophy, and limit extracellular matrix deposition and myocardial fibrosis. 8, 9 NO is generated by three NO synthase isoforms, neuronal NOS1, inducible NOS2, and endothelial NOS3. In cardiac myocytes, NOS3 is targeted to caveolae 10, 11 where compartmentalization with ␤-adrenergic receptors and L-type Ca 2ϩ channels allows NO to inhibit ␤-adrenergic-induced inotropy. 12 Neuronal NO synthase (NOS1) is localized to cardiac sarcoplasmic reticulum and modulates myocardial contractility via intracellular calcium cycling. 13, 14 Increased cardiac NOS1-derived NO production has been suggested to play an important autocrine regulatory role to maintain myocardial contractility after MI in aging rats. 15 We tested the effect of increased myocardial NOS3 expression on LV remodeling after MI. We compared hemodynamic and echocardiographic parameters of LV performance after MI in transgenic mice with cardiomyocyte-restricted overexpression of human NOS3 (NOS3-TG) and in wild-type (WT) littermates. We report that after MI, LV function was better preserved in NOS3-TG than in WT mice.
Materials and Methods

Experimental Animals
The human cDNA encoding NOS3 was ligated into an expression plasmid containing the ␣-myosin heavy chain gene promoter, directing transgene expression in ventricular myocytes. 16 The construct was electroporated together with pPNT, a plasmid containing the neomycin resistance gene, into embryonic stem cells derived from 129/Sv/Ev mice, and neomycin-resistant ES cell clones containing the transgene were identified by PCR. Undifferentiated ␣MHC-NOS3 transgenic ES cells were microinjected in Swiss Webster mice, and transgenic offspring were backcrossed for five generations with C57BL/6 mice to obtain a greater than 95% C57BL/6 background. Wild-type littermates were studied as controls.
In Vitro Analysis of Myocardial NOS3 Overexpression
For details, see the expanded Materials and Methods section in the online data supplement at http://circres.ahajournals.org.
Immunoblot Analysis
To confirm cardiac-selective overexpression of NOS3 in NOS3-TG mice, we adapted the immunoblot protocol reported previously. 17
Immunoprecipitation (IP)
For IP, 250 g aliquots of protein extracts from NOS3-TG and WT hearts were incubated overnight in RIPA buffer containing monoclonal anti-human NOS3 antibodies or goat polyclonal anti-CAV3. The extracts precipitated with anti-CAV3 antibodies samples were probed with an anti-human NOS3 monoclonal antibody, and the extracts precipitated with anti-NOS3 antibodies were probed with anti-CAV3 antibodies.
Immunolocalization and Confocal Analysis
To localize expression of recombinant NOS3 in hearts from transgenic mice, 7-m-thick transverse sections from frozen hearts were immunostained with the monoclonal anti-human NOS3 antibody.
To investigate subcellular localization of the transgene product, isolated cardiomyocytes from adult NOS3-TG and WT mice were prepared and costained with a murine monoclonal antibody recognizing human NOS3 (Becton Dickinson) and a goat polyclonal antibody against caveolin-3 (Santa Cruz, Biotech, USA) or with a rabbit polyclonal antibody recognizing NOS3 (Becton Dickinson) and a murine monoclonal antibody against ryanodine receptor2 (Affinity Bioreagents, UK). Confocal analysis was also performed on 5-m-thick transverse sections from perfusion-fixed and paraffinembedded hearts using the same antibodies.
NOS Enzyme Activity and Expression Levels
To measure NOS3 enzyme activity, L-arginine to L-citrulline conversion was assayed in extracts from hearts using a modification of the method described by Xue et al 18 and Conrad et al. 19 To evaluate the expression levels of the NOS isoforms in the hearts of transgenic mice, real-time quantitative PCR analysis was performed on RNA samples obtained from six WT and seven NOS3-TG mice using specific probes recognizing sequences complementary to murine genes encoding hypoxanthine phospho-ribosyl transferase (HPRT), NOS1, NOS2, and NOS3. Results were expressed as relative copy numbers standardized to levels of the housekeeping HPRT gene, and the average values in NOS3-TG mice were normalized to the average value in WT mice. 20 
Analysis of Myocardial Function at Baseline and After Myocardial Infarction
Echocardiographic Analysis
Myocardial infarction was produced by ligation of the LAD 21 in 2-to 4-month-old NOS3-TG mice and WT littermates, anesthetized with pentobarbital (40 to 70 mg/kg IP). Echocardiograms were obtained after urethane anesthesia (1.4 g/kg) before and 7 and 28 days after MI using a 15-MHz linear probe. Measurements of LV end-diastolic and end-systolic diameters and interventricular septum and posterior wall end-diastolic thicknesses at baseline and 4 weeks after MI were performed by three independent observers who were blinded to the experimental group (M.S.-C., M.P., M.T.). All dimensions were normalized to body surface area and fractional shortening (FS) was calculated from the parasternal short-and long-axis views.
Hemodynamic Measurements at Baseline and After Myocardial Infarction
Hemodynamic measurements of heart rate, blood pressure, and maximal and minimum rates of pressure development (dP/dt max and dP/dt min ) were obtained in mice anesthetized with urethane at baseline and 28 days after MI using a 1.4-F high fidelity Millar pressure catheter.
Response to ␤-Adrenergic Stimulation
In additional NOS3-TG (nϭ15) and WT (nϭ11) mice without MI and anesthetized using 2,2,2-tribromoethanol (22 L/g body weight), heart rate, and systolic and diastolic function (dP/dt max and dP/dt min ) were measured before and during infusion of isoproterenol (0.1, 0.3, 1.0, 3.0, and 10 ng in 20 L saline). 22 
Histological Analysis
Twenty-eight days after LAD occlusion, the left ventricle was weighed, fixed with formaldehyde at a perfusion pressure of 100 cm H 2 O, embedded in paraffin, and sectioned along the short axis into 5-and 7-m-thick slices obtained at 1-mm intervals. After staining with hematoxylin-eosin and Sirius red, the infarcted circumference was traced, and the infarcted area was normalized to LV area. Myocyte width was measured in the remote, noninfarcted area of the LV, and measures were obtained at the level of the nucleus in longitudinally sectioned myocytes. 23 To assess the degree of fibrosis in remote myocardium, a Sirius red and periodic acid Schiff (PAS) histochemical stain was performed on paraffin-embedded sections, and the area of collagen deposition was traced using polarized light and spectral thresholding on a Zeiss Axioplan 2 imaging microscope (Zeiss KS 300 software). The degree of fibrosis was expressed as the area of the remote myocardium containing collagen as a percentage of the total noninfarcted area of the LV surface.
Statistical Analysis
All data are expressed as meanϮSEM unless indicated otherwise. Differences between groups were determined using Student t test or 2-way ANOVA for repeated measurements, where indicated. Significant differences were further analyzed using Bonferroni post hoc tests. A value of PϽ0.05 was considered significant.
Results
Selective Myocardial Overexpression of NOS3
Immunoblot, Immunoprecipitation, and Confocal Analysis Abundant NOS3 immunoreactivity was detected in cardiac myocytes of mice carrying the ␣MHC-NOS3 transgene (NOS3-TG) but not in those from wild-type (WT) mice ( Figure 1A ). The intensity and distribution of recombinant NOS3 were comparable in newborn and in 2-to 4-month old NOS3-TG mice (data not shown). Immunoblot analysis confirmed that high concentrations of 135-kDa NOS3 protein were present in hearts of NOS3-TG mice, whereas in WT mice, immunoreactive NOS3 was detectable at low levels ( Figure 1B) .
To investigate the subcellular localization of the transgene product, immunoprecipitation studies with a caveolin-3-specific antibody were performed. Antibody to caveolin-3 coprecipitated NOS in myocardial extracts from WT mice, but the intensity of the signal for NOS3 was strongly increased in precipitates from hearts of NOS3-TG mice ( Figure 1C staining using ryanodine receptor 2 antibodies clearly demonstrated that the transgene product was not localized in the sarcoplasmic reticulum (data not shown). Confocal microscopy of transverse sections confirmed abundant NOS3 expression in NOS3-TG mice but not in WT, and a high degree of targeting to caveolin (see online data supplement).
NOS Enzyme Activity and Expression Levels
Cardiac extracts from NOS3-TG mice (nϭ5) contained markedly greater NOS enzyme activity than did extracts from WT mice (nϭ7), as reflected by an increase in the ability to convert L-arginine to L-citrulline (100Ϯ51 versus 3.4Ϯ2.9 pmol/mg per min, respectively, PϽ0.05).
To evaluate the impact of the transgene on the expression of the endogenous NOS isoforms, transcript levels of murine NOS1, NOS2, and NOS3, normalized to the constitutive HPRT gene, were compared in NOS3-TG and WT mice (Table 1 and also online data supplement). These results show that cardiomyocyte-specific overexpression of NOS3 does not affect the expression of the other NOS isoforms in the heart.
Analysis of Myocardial Function at Baseline and After Myocardial Infarction
Echocardiographic and Hemodynamic Measurements at Baseline and After Myocardial Infarction
Echocardiographic analysis of LV dimensions revealed that end-diastolic and end-systolic diameters, normalized for body surface area, were comparable in NOS3-TG and WT mice, and that computed measurements of fractional shortening, a load-dependent index of systolic function, did not differ between genotypes (Table 2) . At baseline, heart rate, mean blood pressure, and left ventricular systolic and diastolic function did not differ between WT and NOS3-TG mice (Table 3) .
To determine whether cardiac-selective NOS3 overexpression could modulate LV remodeling after MI, NOS3-TG and WT mice were subjected to LAD coronary artery occlusion. One week after MI, infarct size was 34Ϯ4% (nϭ7) and 36Ϯ12% (nϭ7) in NOS3-TG and WT mice, respectively. Echocardiographic analysis 28 days after MI revealed significantly smaller end-systolic LV internal diameters in NOS3-TG mice than in WT, consistent with significantly improved LV fractional shortening ( Table 2 ). The favorable LV function profile in NOS3-TG mice 28 days after MI, as assessed by transthoracic echocardiography, was confirmed during cardiac catheterization. Heart rate and mean blood pressure were comparable in NOS3-TG and WT mice (Table  3) , whereas indices of LV systolic and diastolic function (dP/dt max and dP/dt min ) indicated enhanced contractile performance and ventricular relaxation in NOS3-TG mice.
LV Weight, Myocyte Size, and Myocardial Fibrosis
Before MI, the LV weight/body weight ratio did not differ in WT and NOS3-TG mice (4.1Ϯ0.4 versus 4.2Ϯ0.4 in WT, nϭ10 and NOS3-TG, nϭ10, respectively). Twenty-eight days after MI, the LV weight/body weight ratio increased in both WT and NOS3-TG mice but was significantly greater in WT than in NOS3-TG mice (Table 3) . Before MI, myocyte width in the remote myocardium did not differ between genotypes (10.8Ϯ0.8 and 10.8Ϯ1.4 m in WT and NOS3-TG mice, respectively), whereas at 28 days after MI, myocyte width was greater in WT than in NOS3-TG mice (Table 3, Figure 3 ). To investigate whether NOS3 overexpression in the myocardium would attenuate post-MI remodeling by reducing fibrosis in noninfarcted remote myocardium, collagen content of the remote myocardium was measured in tissue sections. In WT and NOS3-TG mice, collagen content in the remote myocardium was 5.3Ϯ2.0 and 5.1Ϯ2.2% of the total noninfarcted LV area, respectively (PϭNS).
Finally, to investigate if the favorable hemodynamic profile after MI would translate into a survival benefit in NOS3-TG, we evaluated all cause mortality over the 28 days after LAD occlusion. The majority of deaths occurred in the first week with very few additional deaths beyond 1 week. After 1 month, survival in NOS3-TG mice was 68% versus 58% in WT mice (PϭNS).
Response to ␤-Adrenergic Stimulation
To investigate the impact of transgene expression on the contractile response to ␤-adrenergic stimulation, five incremental doses of isoproterenol (0.1 to 10 ng) were infused in a separate series of animals to obtain a dose-response curve of left ventricular dP/dt max . At baseline, dP/dt max in WT and NOS3-TG mice were not different. At doses greater than 1.0 ng isoproterenol, the inotropic response to ␤-adrenergic stimulation was significantly less in NOS3-TG (nϭ11) than WT mice (nϭ15) (Figure 4 ). Of interest, although baseline heart rates were comparable in WT and NOS3-TG mice (475Ϯ49 versus 478Ϯ42 bpm, respectively), they were slower than in our MI protocol, a finding likely attributable to the different anesthetic regimen. The chronotropic response to maximum isoproterenol stimulation, however, was attenuated in NOS3-TG mice (504Ϯ52 versus 561Ϯ42 bpm in WT; PϽ0.05).
Discussion
In the present study, we demonstrated that cardiac-restricted overexpression of endothelial NOS preserves cardiac function and limits deleterious left ventricular remodeling in a mouse model of myocardial infarction. Recombinant NOS3 was abundantly expressed in cardiomyocytes of transgenic mice and was localized to caveolae, as demonstrated by immunoprecipitation studies and confocal laser scanning microscopy. Increased human NOS3 transcript levels did not affect endogenous expression levels of the constitutive or inducible murine NOS isoforms (Table 1) . Despite 30-fold more cardiac NOS enzymatic activity, transgenic mice developed normally and did not differ at baseline from wild-type mice in terms of hemodynamic measurements or echocardiographic measurements of load-dependent indices of systolic function. Despite similar infarct sizes after LAD ligation in NOS3-TG and WT mice, the former were protected against maladaptive remodeling after MI, as evidenced by a better preserved contractile performance, measured using echocardiography (Table 2) . Also residual LV systolic and diastolic function was better preserved in NOS3-TG, as measured invasively (Table 3 ). Histological analysis demonstrated that LV mass and myocyte width in the noninfarcted remote myocardium were less in NOS3-TG mice (Figure 3) , whereas the degree of fibrosis was not different between the two genotypes. These findings suggest that cardiac-specific overexpression of NOS3 attenuated the development of LV remodeling after MI.
Nitric oxide modulates many processes contributing to LV remodeling after MI. The impact of the constitutive NOS isoforms on contractility and calcium cycling has been investigated in isolated cardiomyocytes from mice with targeted deletion of NOS1 and NOS3. 24 -26 In addition, left ventricular contractile function after MI has been studied in mice with targeted deletions of NOS3 and NOS2, as well as in transgenic mice with systemic overexpression of NOS3 within the vascular endothelium. NOS3 deficiency was associated with maladaptive remodeling 1 month after MI with increased cardiac hypertrophy and reduced LV function. 23 Others did not find a difference in LV remodeling after large MIs in wild-type and NOS3-deficient mice. 27 The differences in the outcomes of these two studies are likely attributable to differences in the sizes of the MIs studied: in large MIs, the LV remodeling response may reach a maximum obscuring any further deleterious effects of NOS3 deficiency. In the latter study, however, angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor type-1 (AT 1 ) antagonists were far less effective in preventing myocardial remodeling and preserving LV function after MI in NOS3-deficient mice than in wild-type mice, emphasizing the importance of NOS3 in the salutary effects of these agents. NOS2 deficiency, in contrast, has been reported to be associated with better survival and improved LV function either early 28 or late 29 after MI, although in the latter study the improved contractility was only observed at the highest level of preload in an artificial in vitro system. However, the effect of NOS2-deficiency on LV remodeling after MI may be influenced importantly by the central role of NOS2 in the cardioprotection associated with myocardial ischemia. 30 The preservation of LV function after MI in our NOS3-TG mice was associated with decreased LV weight and myocyte width. These findings suggest that NOS3-derived NO inhibited myocyte hypertrophy in the remote myocardium in NOS3-TG mice after MI via a paracrine or possibly autocrine mechanism. After MI, a variety of signaling mechanisms stimulate myocyte hypertrophy including the ␤-adrenergic pathway and the renin angiotensin system. 31 We observed that NOS3-TG mice have a significantly reduced inotropic response to ␤-adrenergic stimulation (Figure 4) . Similarly, Brunner et al 32 reported that the contractile response to norepinephrine was impaired in isolated hearts from mice with cardiac NOS3 overexpression, although basal contractile function under these experimental conditions was also reduced. Different baseline characteristics most likely reflect different experimental conditions, whereas similar responses to adrenergic stimulation are consistent with the paradigm developed from experiments on isolated cardiomyocytes that endogenous NOS3-derived NO consistently opposes the inotropic response to ␤-adrenergic stimulation. 33, 34 At the same time, chronotropic responses to ␤-adrenergic stimulation were attenuated in NOS3-TG mice, consistent with a growing consensus that NOS3 in cardiomyocytes reinforces vagal efferent inhibition of heart rate. 35, 36 We speculate that the preservation of LV function and attenuation of LV remodeling observed in NOS3-TG mice may, in part, be attributable to inhibition of the ability of ␤-adrenergic stimuli to induce hypertrophy. At the same time, transgenic mice showed improved diastolic performance after MI, evidenced by the significantly higher rates of LV pressure decline during diastole. Improved systolic and diastolic function may, in turn, decrease the stimulus to remodel after MI.
The protective role of the transgene product on LV remodeling after myocardial infarction did not translate into a survival benefit. In C57BL/6 mice subjected to the same surgical MI model, H. Bayat and colleagues 21 reported LV dilatation and reduced exercise capacity on treadmill testing at 12 to 18 weeks after infarction. Interestingly, and consistent with our findings, mortality occurred only in the early postoperative phase and no additional mortality beyond 2 weeks was reported, even if the animals developed marked congestive heart failure, maladaptive remodeling, and severely impaired left ventricular systolic function 18 weeks after LAD ligation.
We examined whether or not decreased fibrosis in the remote myocardium could contribute to the observed differences in LV contractile function after MI in NOS3-TG and WT mice, but did not find significant differences in collagen deposition using Picrosirius red or PAS stains. It remains to be determined to what extent cardiac-specific NOS3 overexpression modulates the cardiomyocyte apoptosis or myocardial neovascularization, which may also impact LV performance after myocardial infarction.
Recently, S. Jones and colleagues reported that transgenic mice with systemic overexpression of NOS3 within the vascular endothelium had improved survival and decreased pulmonary edema after MI. 37 The benefit in these transgenic mice was attributed to a decrease in LV afterload (and possibly preload), because presence of the transgene was not associated with a beneficial effect on indices of LV remodeling, including cardiac hypertrophy or cardiac contractility. The differences in our findings and those of Jones and colleagues 37 highlight the potential importance of increasing NOS3 expression in cardiomyocytes (rather than in vascular endothelium) to achieve a beneficial impact on LV structure and function after MI.
In summary, cardiomyocyte-restricted overexpression of NOS3 limits LV dysfunction and remodeling after MI, in part by decreasing myocyte hypertrophy in noninfarcted myocardium. Strategies aimed at increasing myocardial NO concentrations such as NOS3 gene transfer (via the coronary arterial or venous circulation) or local (intracoronary or intrapericar- dial) administration of a slow-release NO donor compound may be promising treatments for LV remodeling after MI.
